We are live on ! Find out more
LBA

Letko, Brosseau & Associates Portfolio holdings

AUM $6.2B
1-Year Est. Return 38.92%
This Fund
S&P 500
This Quarter Est. Return
+11.8%
1 Year Est. Return
+38.92%
3 Year Est. Return
+73.78%
5 Year Est. Return
+108.79%
10 Year Est. Return
+308.35%
AUM
$5.82B
AUM Growth
+$595M
Cap. Flow
+$58.3M
Cap. Flow %
1%
Top 10 Hldgs %
37.51%
Holding
100
New
7
Increased
34
Reduced
44
Closed
2

Top Buys

Rank Stock Value
1
BCE icon
BCE
BCE
+$33.7M
2
UPS icon
United Parcel Service
UPS
+$30.2M
3
SLF icon
Sun Life Financial
SLF
+$26.8M
4
LULU icon
lululemon athletica
LULU
+$25.5M
5
ADBE icon
Adobe
ADBE
+$24.7M

Top Sells

Rank Stock Value
1
HBM icon
Hudbay
HBM
+$51.9M
2
HES
Hess
HES
+$18.2M
3
C icon
Citigroup
C
+$14.5M
4
AMRZ
Amrize Ltd
AMRZ
+$13.7M
5
GILD icon
Gilead Sciences
GILD
+$12.5M

Sector Composition

Rank Sector Weight
1 Financials 32.97%
2 Communication Services 19.08%
3 Materials 10.87%
4 Healthcare 9.14%
5 Technology 9.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EMA
76
Emera Inc
EMA
$15.6B
$407K 0.01%
8,485
– –
NXPI icon
77
NXP Semiconductors
NXPI
$60.4B
$404K 0.01%
1,775
– –
FTS icon
78
Fortis
FTS
$28.7B
$401K 0.01%
7,900
-600
-7% -$29.5K
VALE icon
79
Vale
VALE
$62.6B
$398K 0.01%
36,650
– –
ERO icon
80
Ero Copper
ERO
$3.58B
$365K 0.01%
18,000
+3,500
+24% +$53.3K
NAMS icon
81
NewAmsterdam Pharma
NAMS
$3.34B
$335K 0.01%
11,775
– –
MSFT icon
82
Microsoft
MSFT
$3.71T
$330K 0.01%
638
– –
PVLA
83
Palvella Therapeutics
PVLA
$2.27B
$326K 0.01%
+5,200
New +$232K
FCX icon
84
Freeport-McMoran
FCX
$97.5B
$272K ﹤0.01%
6,925
– –
GOOGL icon
85
Alphabet (Google) Class A
GOOGL
$4.33T
$265K ﹤0.01%
+1,092
New +$229K
MGTX icon
86
MeiraGTx Holdings
MGTX
$1.21B
$263K ﹤0.01%
32,000
-13,300
-29% -$105K
AMRZ
87
Amrize Ltd
AMRZ
$25.8B
$256K ﹤0.01%
5,316
-268,832
-98% -$13.7M
SPRY icon
88
ARS Pharmaceuticals
SPRY
$612M
$248K ﹤0.01%
24,700
– –
MLYS icon
89
Mineralys Therapeutics
MLYS
$2.41B
$208K ﹤0.01%
5,475
-11,025
-67% -$238K
ALB icon
90
Albemarle
ALB
$15.5B
$201K ﹤0.01%
+2,475
New +$191K
AURA icon
91
Aura Biosciences
AURA
$826M
$175K ﹤0.01%
28,300
+7,100
+33% +$46.4K
TCRX icon
92
TScan Therapeutics
TCRX
$52M
$174K ﹤0.01%
95,875
– –
ETNB
93
DELISTED
89bio
ETNB
$157K ﹤0.01%
10,700
– –
GOSS icon
94
Gossamer Bio
GOSS
$87M
$104K ﹤0.01%
+39,400
New +$86.8K
ALDX icon
95
Aldeyra Therapeutics
ALDX
$93.5M
$90.3K ﹤0.01%
17,300
– –
HUMA icon
96
Humacyte
HUMA
$194M
$80K ﹤0.01%
45,950
– –
REPL icon
97
Replimune Group
REPL
$1.01B
$45.3K ﹤0.01%
10,800
– –
PROK icon
98
ProKidney
PROK
$337M
$38.5K ﹤0.01%
+15,900
New +$42.3K
HES
99
DELISTED
Hess
HES
– –
-131,417
Closed -$18.2M
SKX
100
DELISTED
Skechers
SKX
– –
-6,725
Closed -$424K
1 2 3
4

Similar funds

NP
NorthRock Partners Minneapolis, Minnesota $6.2B AUM 15.8% 1-Year Est. Return
WIA
World Investment Advisors Santa Barbara, California $6.2B AUM 19.68% 1-Year Est. Return
CA
Cambridge Associates Boston, Massachusetts $6.27B AUM 14.78% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
OMC
Old Mission Capital Chicago, Illinois $6.3B AUM 14.68% 1-Year Est. Return

Letko, Brosseau & Associates's Q3 2025 Portfolio in Review

As of Q3 2025, Letko, Brosseau & Associates held 100 positions worth $5.82B, up 11% from $5.23B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Letko, Brosseau & Associates's Q3 2025 filing shows 7 new, 34 increased, 44 reduced and 2 closed positions. Its largest new stake was Chevron: 133,429 shares worth $20.7M. The largest sale was Hudbay, an estimated $51.9M.

By sector, the portfolio is most concentrated in Financials at 33% of assets, down from 34% a quarter earlier, followed by Communication Services and Materials.

  • Letko, Brosseau & Associates's largest Q3 2025 buy was Chevron: 133,429 shares worth $20.7M.
  • Letko, Brosseau & Associates added most to BCE in Q3 2025, an estimated $33.7M increase.
  • Letko, Brosseau & Associates's biggest Q3 2025 reduction was Hudbay, cutting an estimated $51.9M.
  • Letko, Brosseau & Associates fully exited Hess in Q3 2025, selling an estimated $18.2M.
  • Letko, Brosseau & Associates's ten largest holdings make up 38% of its $5.82B portfolio in Q3 2025.
  • Letko, Brosseau & Associates opened 7 new positions and closed 2 in Q3 2025.
  • Letko, Brosseau & Associates's portfolio value rose 11% quarter-over-quarter to $5.82B.

Based on Letko, Brosseau & Associates's 13F filing for Q3 2025, filed 12 Nov 2025.